FAA Advisory ays System Failure Is Impacting Flights Nationwide, Flights Reportedly Grounded Across US
https://twitter.com/ALorenzoTV/status/1613130786949009409
Snow Lake Lithium Announces Drill Results Of 2022 Grass River Drilling Campaign
Results:
2.0 % Li2O over 16 meters starting at 30.9 meters down hole (CBP-007)
Including 3.1 % Li2O over 1.5 meters
1.8 % Li2O over 3.0 meters starting at 210.3 meters down hole (GRP-018)
Including 3.6 %
Wejo Group Limited Enters Into Business Combination With TKB Critical Technologies 1; Expected To Provide Up To $100M In Capital To Wejo
Definitive Business Combination Agreement Expected to Provide up to $100 Million in Capital to Wejo and $11.25 per Share for TKB Shareholders
Company to Provide a Business Update on Tuesday, January
BIOLASE Prices $9.75M Offering
BIOLASE, Inc. (NASDAQ:BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the pricing of an underwritten public offering consisting of 16,453,569 shares of its common
‘NIO Becomes the Second-Largest BEV Manufacturer in China by Revenue at the Start of 2023’ -Wccftech
https://www.twitter.com/i/status/1612791125458452480
TSR Q2 EPS $0.30 Up From $0.12 YoY, Sales $26.00M Up From $23.86M YoY
TSR (NASDAQ:TSRI) reported quarterly earnings of $0.30 per share. This is a 150 percent increase over earnings of $0.12 per share from the same period last year. The company reported $26.00 million in sales this
Nicola Mining Inc. And Osisko Development Corp. Enter Into Mining And Milliing Profit Share Agreement
Nicola Mining Inc. (TSXV:NIM)(FSE: HLI), (the "Company" or "Nicola") is pleased to announce that it and Osisko Development Corp. (NYSE:ODV) (TSXV:ODV) ("Osisko") have signed a Mining and
Daré Bioscience Announces Pharmacokinetic Results From DARE-HRT1 Phase 1 / 2 Study That Support Potential Pf DARE-HRT1 As Hormone Therapy For Both Vasomotor And Vaginal Symptoms of Menopause
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause
DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal